Small portions of zinc (0.451 g, 6.89 mmol) were added to the stirring reaction mixture at 25 °C.
[Caution: Exotherm, gas evaluation] Reaction mixture was stirred for next 6 h. Volatile substances were evaporated off. To the residues, 25 mL of MeOH:DCM (1:1) was added and triturated for 10 min., inorganic residues were filtered off. The filtrate was evaporated and the residue was purified via Biotage flash column chromatography (MeOH:DCM 0-10%) afforded 
N-(2-oxoindolin-5-yl)ethanesulfonamide (12)
To a solution of 5-nitroindolin-2-one (8.5 g, 47.7 mmol) in MeOH (87 mL, 2147 mmol) and water (8.60 mL, 477 mmol) was added ammonium chloride (7.66 g, 143 mmol). Reflux condencer was fixed to RBF and at 25 °C to the reaction mixture added zinc (6.24 g, 95 mmol) in portions
[Caution: Exothermic, vigrous gas evaluation]. Continued stirring for next 6 h, after completion of the reaction, volatile substances were evaporated off under reduced pressure to ensure no S7 trace of water present in the reaction mass. The solid mass was triturated with 15 mL of DMF, warmed it to 50 °C to dissolve maximum amount of product and solid inorganic salts and residues were filtered off, washed with 2 mL of DMF. In RBF to the combine DMF filtrate, added triethylamine (6.65 mL, 47.7 mmol) followed by ethanesulfonyl chloride (4.52 mL, 47.7 mmol) at 0 °C. Reaction mixture was stirred at 25 °C for 12 h. LCMS confirmed the product formation.
Volatile substances were evaporated off under reduced pressure and the residue was purified Organic volatile substances were evaporated off under reduced pressure and crude reaction mass was loaded on Biotage column (DCM prime before loading, eluted in 0-25% MeOH-DCM).
In case where the fractions were not pure enough, most purified fractions were combined, evaporated and re purified by Prep. HPLC. N-(2-oxo-3-(1-((4-(piperidin-1-ylmethyl) 
(Z)-N-(3-(((1-methylpiperidin-4-yl)amino)(phenyl)methylene)-2-oxoindolin-5-

(Z)-N-(2-oxo-3-(1-((4-(piperidin-1-ylmethyl)phenyl)amino)pentylidene)indolin-
cells/well). Cells
were incubated for 2 h to allow for attachment. Compounds were then added at the specified concentrations. To each well, 100 μL of parasites (T. cruzi expressing β-galactosidase) in the aforementioned media were added at a concentration of 5x10 5 cells/mL (5x10 4 cells/well) and incubated at 37°C, 5% CO 2 for 96 h. Following incubation, 50 μL of 500 μM chlorophenol Red-β-D-galactopyranoside (CPRG) in PBS with 0.5% IGEPAL CA-630 was added to each well and incubated at 37°C, 5% CO 2 for 4 hours. Absorbance was read at 590-595 nm.
Leishmania major promastigotes.
The promastigote assay is a microtiter plate drug sensitivity prescreen assay used to determine antileishmanial activity of candidate drugs against promastigote forms of L. major. Alamar Blue, or resazurin, is a non-fluorescent indicator dye that is converted to bright red-fluorescent resorufin via the activity of mitochondrial reductases.
As the activity of mitochondrial reductases is reduced in cells that are dead or dying, and the intensity of the fluorescence is relative to cell number, a test compound that kills or inhibits S13 growth of a particular target cell, such as L. major, will result in a lower production of fluorescent signal. This simple assay is widely used for both toxicity and proliferation assays, and it was adapted for use in Leishmania drug discovery as shown by Sharlow. 2 Pre-dosed microtiter drug plates for use in the promastigote drug prescreen assay were produced using sterile 384-well black optical bottom tissue culture plates. Candidate drugs were diluted in dimethyl sulfoxide in four 96-well plates to either 10,000 ng/ml or 1,000 ng/ml, and 4.25 µLof diluted drug was subsequently dispensed into each well of a 384-well plate. Duplicate 384 well plates were made at each test concentration (10,000 ng/mL and 1,000 ng/mL) and amphotericin B was used as a Leishmania major amastigotes. 3 The intracellular amastigote assay is a microtiter plate drug sensitivity assay that uses the activity of luciferase as a measure of proliferation of luciferaseexpressing L. major parasites developing intracellularly inside RAW 264.7 macrophages in the presence of antileishmanial drugs or experimental compounds. As the activity of luciferase and its associated luminescence after addition of the substrate, luciferin, is relative to parasite S14 growth, a test compound that inhibits the growth of the parasite will result in a lower luminescence. The luciferase-expressing L. major parasite used in this assay is genetically modified by adding the luciferase coding region to the pLEXSY-hyg2 vector (Jena Biosciences).
The luciferase expression construct was created by digesting the luciferase coding region (1.66kbp) of pGL3-Basic (Promega) by using two restriction enzymes, NcoI/EagI, followed by electrophoretic separation of the luciferase coding region on a 1% agarose gel. The luciferase coding region was then ligated into pLEXSY-hyg2 vector (Jena Biosciences) which had previously been digested with NcoI/NotI. The vector was linearized with SwaI and subsequently gel purified prior to transfection into L. major parasites. Transfections were carried out by electroporation at 480V, 13 Ω, and 500µF (0.4mL of 1x10 8 parasites/mL, and 0.1mL of 10µg DNA). Selection for transfectants was then carried out using hygromycin B (100µg/mL). RAW 264.7 macrophages were cultured in DMEM media supplemented with heat-inactivated 10%
FBS. To begin the assay, macrophages were harvested from culture by removing all spent media, adding in 10mL fresh media, scraping cells, and counted using Trypan Blue. The cells were resuspended in DMEM/10% HIFBS media at 2.0x10 5 cells/mL, and then dispensed in a volume of 50 µL to yield a final concentration of 10,000 macrophages/well in 384 well tissueculture treated sterile white plates using a Tecan EVO Freedom robotics system. The plates were then incubated at 37 o C in 5% CO 2 atmosphere for 24 hours. After incubation, the media was removed from each well using the Tecan EVO Freedom robot, and L. major promastigotes were added to each well and allowed to invade the RAW macrophages. Promastigotes were cultured in Schneider's medium supplemented with 20% heat inactivated FBS. Metacyclic stage promastigotes provide the best invasion for this assay, and cultures should be grown to increase the percentage of metacyclic promastigotes for best results. Promastigotes were harvested from culture, counted, suspended at 2x10 6 promastigotes/mL in DMEM/HIFBS media, and 100,000 promastigotes were dispensed per well in a volume of 50 µL. After overnight incubation, the media was removed from each well using the Tecan Freedom EVO robot, and S15 each well was subsequently washed three times with 40 µL of fresh DMEM/HIFBS medium to remove all extracellular promastigotes. After the third wash, 69.2µL of DMEM/HIFBS medium was added to each well using the Tecan EVO Freedom robot. Drug plates were prepared with the Tecan EVO Freedom using sterile 96 well plates containing twelve duplicate two-fold serial dilutions of each test compound suspended in DMSO. 7.8 µL of diluted test compound was added to the 69.2 µL of media present in each well providing a 10 fold final dilution of compound. The final concentration range tested was 0.5 to 10,000 ng/ml for all assays. The plates were next incubated at 37°C and 5% CO 2 for 96 hours. After 96 hours of incubation, 7.5 µL of a luciferin solution (Caliper Life Science) diluted to 150µg/mL was added to each well, and the plates were incubated for 30 minutes at 37°C, in the dark. Each plate was read using a Infinite M200 plate reader. The 50% inhibitory concentrations (IC 50 s) were then generated for each dose response test using GraphPad Prism (GraphPad Software Inc., San Diego, CA) using the nonlinear regression (sigmoidal dose-response/variable slope) equation.
Plasmodium falciparum assay. The SYBR Green fluorescence (MSF) Assay is a microtiter plate drug sensitivity assay that uses the presence of malarial DNA as a measure of parasitic proliferation in the presence of antimalarial drugs or experimental compounds. As the intercalation of SYBR Green I dye and its resulting fluorescence is relative to parasite growth, a test compound that inhibits the growth of the parasite will result in a lower fluorescence. D6
(CDC/Sierra Leone), TM91C235 (WRAIR, Thailand), and W2 (CDC/Indochina III) laboratory strains of P. falciparum were used for each drug sensitivity assessment. The parasite strains were maintained continuously in long-term cultures as previously. 4 Pre-dosed microtiter drug plates for use in the MSF assay were produced using sterile 384-well black optical bottom tissue HepG2 Toxicity Assay. 6 The MTT counter screen assay is an in vitro microtiter toxicology test used to determine toxicity of drug compounds against the primary target of interest, such as a HepG2 liver cell, determine the relative toxicity of one compound versus another within a chemical series, aid in determining the toxicology structure relationship within a chemical series, and prioritize compounds for advancement for in vivo studies. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a monotetrazolium salt that is reduced by mitochondria S17 reductases to create a formazan dye, which has a purple color. As the activity of mitochondrial reductases is reduced in cells that are dead or dying, and the intensity of the purple color is relative to cell number and metabolism, a test compound that is toxic to a particular target cell, such as the HepG2 liver cell, will result in a lower production of formazan dye and reduced purple color. This simple colorimetric test is widely used for both toxicity and proliferation assays. The MTT counterscreen is used in concert with the malaria inhibition of liver stage development assay (ILSDA) as a toxicity counter screen. Interpretation of the IC 50 determination of potentially malaria liver stage active compounds requires a toxicity test to insure that the activity observed is specific to malaria and not simply toxicity directed against a HepG2 cell. The 384 well MTT cytotoxicity assay is a modification of the MTT method described by Ferrari to 10,000 ng/ml for all assays. Mefloquine was used as a plate control for all assays with a concentration ranging from 113 ng/ml to 20,000 ng/ml. After a 48 hour incubation period, 8 µL of S18 a 1.5 mg/ml solution of MTT diluted in complete MEM media was added to each well. All plates were subsequently incubated in the dark for 1 hour at room temperature. After incubation, the media and drugs in each well was removed by shaking the plate over sink, and the plates were left to dry in a fume hood for 15 minutes. Next, 30 µL of isopropanol acidified by addition of HCl at a final concentration of 0.36% was added to dissolve the formazan dye crystals created by reduction of MTT. Plates are put on a 3-D rotator for 15-30 minutes. Absorbance was determined in all wells using a Tecan iControl 1.6 Infinite plate reader. The 50% inhibitory concentrations (IC50s) were then generated for each toxicity dose response test using GraphPad Prism (GraphPad Software Inc., SanDiego, CA) using the nonlinear regression (sigmoidal dose-response/variable slope) equation.
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